Seizures in Primary Antiphospholipid Syndrome: The Relevance of Smoking to Stroke

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCARVALHO, Jozelio Freire de
dc.contributor.authorPASOTO, Sandra Gofinet
dc.contributor.authorAPPENZELLER, Simone
dc.date.accessioned2013-07-30T17:17:27Z
dc.date.available2013-07-30T17:17:27Z
dc.date.issued2012
dc.description.abstractObjectives. To evaluate the frequency of seizures in primary antiphospholipid syndrome (PAPS) and their possible clinical and laboratory associations. Methods. Eighty-eight PAPS patients (Sydney's criteria) were analyzed by a standard interview, physical examination and review of medical charts. Risk factors for seizures, clinical manifestations, associated comorbidities, and antiphospholipid antibodies were evaluated. Results. Nine (10.2%) patients with seizures were identified, 77.8% had convulsions onset after PAPS diagnosis. Mean age, gender, and race were comparable in groups with or without seizures. Interestingly, a higher frequency of current smoking (44.4 versus 10.1%, P = 0.019) was observed in the first group. Stroke, Sneddon's syndrome, and livedo reticularis were more frequent in PAPS patients with seizures than those without seizures, although not statistically significant (P > 0.05). Comparison between patients with seizures onset after PAPS diagnosis (n = 7) and those without convulsions (n = 79) demonstrated a higher frequency of current smoking (42.9 versus 10%, P = 0.042) and stroke in the first group (71.4 versus 30.4%, P = 0.041). Regression analysis confirmed that smoking (P = 0.030) and stroke (P = 0.042) were independently associated to seizures. Conclusion. About 10.2% of PAPS patients had convulsions, predominantly after PAPS diagnosis, and seizures were associated to current smoking and stroke.
dc.description.indexMEDLINE
dc.description.sponsorshipFederico Foundation
dc.description.sponsorshipCNPq [300665/2009-1]
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2008/02917-0, 2010/10013-4, 2009/06049-6]
dc.identifier.citationCLINICAL & DEVELOPMENTAL IMMUNOLOGY, article ID 981519, 7p, 2012
dc.identifier.doi10.1155/2012/981519
dc.identifier.issn1740-2522
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1233
dc.language.isoeng
dc.publisherHINDAWI PUBLISHING CORPORATION
dc.relation.ispartofClinical & Developmental Immunology
dc.rightsopenAccess
dc.rights.holderCopyright HINDAWI PUBLISHING CORPORATION
dc.subject.othersystemic-lupus-erythematosus
dc.subject.othernicotine-induced seizures
dc.subject.otherepileptic seizures
dc.subject.othersyndrome aps
dc.subject.otherrisk-factors
dc.subject.otherdisease
dc.subject.otherantibodies
dc.subject.othermanifestations
dc.subject.othersensitivity
dc.subject.otherthrombosis
dc.subject.wosImmunology
dc.titleSeizures in Primary Antiphospholipid Syndrome: The Relevance of Smoking to Stroke
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalAPPENZELLER, Simone:Univ Estadual Campinas, Div Rheumatol, Fac Med, Hosp Clin, Campinas, SP, Brazil
hcfmusp.citation.scopus29
hcfmusp.contributor.author-fmusphcJOZELIO FREIRE DE CARVALHO
hcfmusp.contributor.author-fmusphcSANDRA GOFINET PASOTO
hcfmusp.description.articlenumber981519
hcfmusp.description.volume2012
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed22489254
hcfmusp.origem.scopus2-s2.0-84859702154
hcfmusp.origem.wosWOS:000302596000001
hcfmusp.publisher.cityNEW YORK
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAppenzeller S, 2004, NEUROLOGY, V63, P1808
hcfmusp.relation.referenceArbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933
hcfmusp.relation.referenceASHERSON RA, 1989, AM J MED, V86, P391, DOI 10.1016/0002-9343(89)90335-5
hcfmusp.relation.referenceBensenor IM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-298
hcfmusp.relation.referenceBlume Warren T., 2001, Epilepsia, V42, P1212, DOI 10.1046/j.1528-1157.2001.22001.x
hcfmusp.relation.referenceBroide RS, 2002, MOL PHARMACOL, V61, P695, DOI 10.1124/mol.61.3.695
hcfmusp.relation.referenceCervera R, 2002, ARTHRITIS RHEUM, V46, P1019, DOI 10.1002/art.10187
hcfmusp.relation.referenceChapman J, 1999, LUPUS, V8, P127, DOI 10.1191/096120399678847524
hcfmusp.relation.referenceCOCITO L, 1982, STROKE, V13, P189
hcfmusp.relation.referenceDEFIEBRE CM, 1988, ALCOHOL, V5, P55, DOI 10.1016/0741-8329(88)90044-4
hcfmusp.relation.referenceDworetzky BA, 2010, EPILEPSIA, V51, P198, DOI 10.1111/j.1528-1167.2009.02268.x
hcfmusp.relation.referenceErkan D, 2007, ARTHRITIS RHEUM, V56, P2382, DOI 10.1002/art.22663
hcfmusp.relation.referenceErkan D, 2009, NAT CLIN PRACT RHEUM, V5, P160, DOI 10.1038/ncprheum1017
hcfmusp.relation.referenceESPARZA RH, 1985, J RHEUMATOL, V12, P1109
hcfmusp.relation.referenceFisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x
hcfmusp.relation.referenceGualtierotti R., CLIN REV AL IN PRESS
hcfmusp.relation.referenceHUGHES GRV, 1983, BRIT MED J, V287, P1088
hcfmusp.relation.referenceLIOU HH, 1994, LIFE SCI, V54, P1119, DOI 10.1016/0024-3205(94)00422-6
hcfmusp.relation.referenceMiyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
hcfmusp.relation.referenceMOORE PM, 1995, SPRINGER SEMIN IMMUN, V17, P43
hcfmusp.relation.referencePierangeli SS, 2008, NAT PROTOC, V3, P840, DOI 10.1038/nprot.2008.48
hcfmusp.relation.referenceRibeiro AR, 2010, ACTA REUMATOL PORT, V35, P36
hcfmusp.relation.referenceRodrigues CEM, 2010, EUR J CLIN INVEST, V40, P350, DOI 10.1111/j.1365-2362.2010.02263.x
hcfmusp.relation.referenceRuiz-Irastorza G, 2010, LANCET, V376, P1498, DOI 10.1016/S0140-6736(10)60709-X
hcfmusp.relation.referenceSanders R. W., 2009, J EMERGENCY MED
hcfmusp.relation.referenceSanna G, 2003, RHEUMATOLOGY, V42, P200, DOI 10.1093/rheumatology/keg080
hcfmusp.relation.referenceShoenfeld Y, 2004, J RHEUMATOL, V31, P1344
hcfmusp.relation.referenceTan EM, 1980, MANUAL CLIN IMMUNOLO, P866
hcfmusp.relation.referenceWisloff F, 2002, THROMB RES, V108, P263, DOI 10.1016/S0049-3848(02)00400-0
hcfmusp.relation.reference[Anonymous], 2006, IDF CONS WORLDW DEF
hcfmusp.remissive.sponsorshipCNPq
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.remissive.sponsorshipFederico Foundation
hcfmusp.remissive.sponsorshipCNPq
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.remissive.sponsorshipFederico Foundation
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationf1d1fb24-f148-469f-ae18-ecdf98f11efc
relation.isAuthorOfPublication6032e83a-1e45-4687-b844-e1ef69997c95
relation.isAuthorOfPublication.latestForDiscoveryf1d1fb24-f148-469f-ae18-ecdf98f11efc
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_CARVALHO_Seizures_in_Primary_Antiphospholipid_Syndrome_The_Relevance_of_2012.PDF
Tamanho:
91.54 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17